{"doi":"10.1016/j.jhep.2021.08.018","title":"Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma","abstract":null,"journal":"Journal of Hepatology","year":2022,"id":653864,"datarank":1.4963126036261236,"base_score":3.6375861597263857,"endowment":3.6375861597263857,"self_citation_contribution":0.5456379239589579,"citation_network_contribution":0.9506746796671657,"self_endowment_contribution":0.5456379239589579,"citer_contribution":0.9506746796671657,"corpus_percentile":null,"corpus_rank":null,"citation_count":37,"citer_count":30,"citers_with_citation_signal":17,"citers_with_endowment":17,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1706159,"name":"Lilia Goudeva","orcid":null,"position":1,"is_corresponding":false},{"id":663703,"name":"Marc Lütgehetmann","orcid":"0000-0002-9468-7944","position":2,"is_corresponding":false},{"id":978083,"name":"Jürgen J. Wenzel","orcid":"0000-0001-8422-6581","position":3,"is_corresponding":false},{"id":1256341,"name":"Patrick Behrendt","orcid":"0000-0001-5750-4259","position":4,"is_corresponding":false},{"id":1014758,"name":"Heiner Wedemeyer","orcid":"0000-0003-2906-0480","position":5,"is_corresponding":false},{"id":1706160,"name":"Albert Heim","orcid":"0000-0002-9447-1561","position":6,"is_corresponding":false},{"id":1706158,"name":"Anne K. Cordes","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma","abstract":"<h4>Background and aims</h4>Immunocompromised patients are at risk of chronic hepatitis E which can be acquired by blood transfusions. Currently, screening of blood donors (BDs) for HEV RNA with a limit of detection (LOD) of 2,000 IU/ml is required in Germany. However, this may result in up to 440,000 IU of HEV RNA in blood products depending on their plasma volume. We studied the residual risk of transfusion-transmitted (tt) HEV infection when an LOD of 2,000 IU/ml is applied.<h4>Methods</h4>Highly sensitive individual donor testing for HEV RNA on the Grifols Procleix Panther system (LOD 7.89 IU/ml) was performed. HEV loads were quantified by real-time PCR.<h4>Results</h4>Of 16,236 donors, 31 (0.19%) were HEV RNA positive. Three BDs had viral loads between 710 and 2,000 IU/ml, which pose a significant risk of tt hepatitis E with any type of blood product. Eight BDs had viral loads of >32 to 710 IU/ml, which pose a risk of tt hepatitis E with platelet or plasma transfusions because of their higher plasma volume compared to red blood cell concentrates. Eight of these 11 potentially infectious BDs were seronegative for HEV, indicating a recent infection. Only 8 of 31 donors had viral loads >2,000 IU/ml that would also have been detected by the required screening procedure and 12 had very low HEV loads (<32 IU/ml).<h4>Conclusions</h4>Screening of BDs with an LOD of 2,000 IU/ml reduced the risk of tt HEV infection by about 73% for red blood cell concentrates but by just 42% for platelet and fresh frozen plasma transfusions. Single donor screening (LOD <32 IU/ml) should lead to an almost 100% risk reduction.<h4>Lay summary</h4>Immunocompromised patients, such as solid organ or hematopoietic stem cell recipients, are at risk of chronic hepatitis E, which can be acquired via blood transfusions. The risk of transfusion-transmitted hepatitis E in these patients may not be sufficiently controlled by (mini-)pool hepatitis E virus RNA screening of blood donors. Single donor screening should be considered to improve the safety of blood products.","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34461207","pmcid":null,"openalex_id":null,"authors":[],"funders":[],"total_grants":0,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0168827821020134?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0168827821020134?httpAccept=text/plain","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Hepatitis E virus","Hepatitis E","Blood Transfusion","Donor Selection","Incidence","Risk Assessment","Statistics, Nonparametric","Prospective Studies","Adult","Middle Aged","Germany","Female","Male","Transfusion Reaction"],"keywords":["HEV","Blood Donor Screening","Individual Donor Testing","Transfusion-transmitted Hepatitis E"],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-11T01:37:16.292249Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}